Interferon gamma-1b

Interferon gamma-1b

File:Interferon gamma-1b.png

Structure of Interferon gamma-1b

Interferon gamma-1b is a recombinant form of human interferon gamma, a cytokine that plays a crucial role in the immune response against viral and bacterial infections, as well as in the regulation of immune system functions. It is used as a therapeutic agent for various medical conditions, including chronic granulomatous disease, osteopetrosis, and malignant osteopetrosis.

History

Interferon gamma-1b was first developed by researchers at the Biogen Idec (now Biogen) in the late 1980s. It was initially derived from human leukocytes and then produced using recombinant DNA technology. The recombinant form of interferon gamma-1b was approved by the U.S. Food and Drug Administration (FDA) in 1992 for the treatment of chronic granulomatous disease.

Mechanism of Action

Interferon gamma-1b exerts its therapeutic effects by binding to specific receptors on the surface of target cells, leading to the activation of various signaling pathways. This activation results in the induction of several immune-related genes, including those involved in the production of antimicrobial peptides, regulation of antigen presentation, and enhancement of natural killer cell activity.

Medical Uses

Interferon gamma-1b is primarily used in the treatment of chronic granulomatous disease (CGD), a rare genetic disorder characterized by recurrent bacterial and fungal infections. It helps to enhance the immune response in CGD patients, reducing the frequency and severity of infections.

Additionally, interferon gamma-1b has shown efficacy in the treatment of osteopetrosis, a rare bone disorder characterized by increased bone density. It helps to improve bone remodeling and reduce the risk of fractures in patients with this condition.

Administration

Interferon gamma-1b is administered via subcutaneous injection. The dosage and frequency of administration depend on the specific medical condition being treated and the patient's response to the therapy. It is usually prescribed by a healthcare professional and should be administered under medical supervision.

Side Effects

Common side effects of interferon gamma-1b include flu-like symptoms such as fever, chills, fatigue, and muscle aches. These symptoms are usually mild and transient. Less common side effects may include headache, nausea, vomiting, and injection site reactions.

Precautions

Interferon gamma-1b should be used with caution in patients with a history of depression or other psychiatric disorders, as it may exacerbate these conditions. It should also be used cautiously in patients with liver or kidney dysfunction, as it can affect the function of these organs.

Conclusion

Interferon gamma-1b is a valuable therapeutic agent used in the treatment of chronic granulomatous disease, osteopetrosis, and malignant osteopetrosis. It plays a crucial role in enhancing the immune response against infections and regulating immune system functions. While it is generally well-tolerated, it is important to be aware of its potential side effects and use it under medical supervision.

References

1. FDA Prescribing Information for Interferon gamma-1b. 2. Gungor T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436-448.

3. Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4:5.

Interferon gamma-1b Resources
Latest articles Most recent articles Ongoing trials	Wikipedia